Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $100
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $100.
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $100.